evERA trial
-
Giredestrant Significantly Improves Progression-Free Survival in ER-Positive Advanced Breast Cancer: Positive Phase III Results
Genentech’s Phase III evERA study demonstrated that giredestrant plus everolimus significantly improved progression-free survival (PFS) in ER-positive, HER2-negative advanced breast cancer patients who progressed after CDK4/6 inhibitor therapy, compared to standard-of-care plus everolimus. This benefit was seen in both ITT and ESR1-mutated populations. The all-oral combination was well-tolerated with no new safety signals. evERA is the first positive Phase III trial of an all-oral SERD-containing regimen. Data will be shared with health authorities.
